Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3
- PMID: 21102472
- PMCID: PMC3739187
- DOI: 10.1038/aja.2010.120
Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3
Erratum in
- Asian J Androl. 2011 Mar;13(2):348
Figures

Comment in
-
Is 37LRP cell surface receptor for PSP94?Asian J Androl. 2011 Mar;13(2):347. doi: 10.1038/aja.2010.185. Epub 2011 Feb 7. Asian J Androl. 2011. PMID: 21297657 Free PMC article. No abstract available.
Comment on
-
Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific.Asian J Androl. 2010 Sep;12(5):677-89. doi: 10.1038/aja.2010.56. Epub 2010 Aug 2. Asian J Androl. 2010. PMID: 20676114 Free PMC article.
Similar articles
-
Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific.Asian J Androl. 2010 Sep;12(5):677-89. doi: 10.1038/aja.2010.56. Epub 2010 Aug 2. Asian J Androl. 2010. PMID: 20676114 Free PMC article.
-
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.Clin Cancer Res. 2007 Jul 15;13(14):4130-8. doi: 10.1158/1078-0432.CCR-06-3031. Clin Cancer Res. 2007. PMID: 17634540 Free PMC article.
-
Purification and characterization of CRISP-3 from human seminal plasma and its real-time binding kinetics with PSP94.J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 15;1039:59-65. doi: 10.1016/j.jchromb.2016.10.032. Epub 2016 Oct 26. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 27825912
-
Structural and molecular biology of PSP94: Its significance in prostate pathophysiology.Front Biosci (Landmark Ed). 2018 Jan 1;23(3):535-562. doi: 10.2741/4604. Front Biosci (Landmark Ed). 2018. PMID: 28930560 Review.
-
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.Prostate. 2010 Feb 15;70(3):333-40. doi: 10.1002/pros.21059. Prostate. 2010. PMID: 19790236 Review.
Cited by
-
Is 37LRP cell surface receptor for PSP94?Asian J Androl. 2011 Mar;13(2):347. doi: 10.1038/aja.2010.185. Epub 2011 Feb 7. Asian J Androl. 2011. PMID: 21297657 Free PMC article. No abstract available.
-
CAP superfamily proteins in human: a new target for cancer therapy.Med Oncol. 2024 Nov 5;41(12):306. doi: 10.1007/s12032-024-02548-6. Med Oncol. 2024. PMID: 39499355 Review.
References
-
- Whitaker HC, Warren AY, Eeles R, Kote-Jrai Z, Neal DE. The potential value of microseminoprotein-β as a prostate cancer biomarker and therapeutic target. Prostate. 2010;70:333–340. - PubMed
-
- Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol. 2006;175:1291–7. - PubMed
-
- Kosari F, Asmann YW, Cheville JC, Vasmatzis G. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1419–26. - PubMed
-
- Bjartell AS, Johansson R, Björk T, Gadaleanu V, Lundwall A, et al. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate. 2006;66:591–603. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical